Technical Analysis for ADVM - Adverum Biotechnologies, Inc.

Grade Last Price % Change Price Change
C 1.65 -6.78% -0.12
ADVM closed up 4.12 percent on Monday, March 18, 2024, on 58 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Mar 28
*** please verify all earnings dates ***
5 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish -6.78%
Lower Bollinger Band Walk Weakness -6.78%
Lower Bollinger Band Touch Weakness -6.78%
Oversold Stochastic Weakness -6.78%
Volume Surge Other -2.94%
Below Lower BB Weakness -2.94%
Down 3 Days in a Row Weakness -2.94%
Lower Bollinger Band Touch Weakness -2.94%
Oversold Stochastic Weakness -2.94%
Below Lower BB Weakness -4.62%

   Recent Intraday Alerts

Alert Time
50 DMA Support 3 minutes ago
200 DMA Support 3 minutes ago
Gapped Down (Full) 22 minutes ago
50 DMA Resistance 22 minutes ago
Down 5% 22 minutes ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Adverum Biotechnologies, Inc. Description

Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Disease Gene Therapy Macular Degeneration Genetic Diseases Retina Wet Age Related Macular Degeneration Rare Genetic Disease Gene Therapy Of The Human Retina Regeneron Adverum Biotechnologies Gene Therapy Products

Is ADVM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.97
52 Week Low 0.681
Average Volume 2,484,508
200-Day Moving Average 1.41
50-Day Moving Average 1.56
20-Day Moving Average 1.90
10-Day Moving Average 1.81
Average True Range 0.19
RSI (14) 48.98
ADX 34.49
+DI 23.81
-DI 18.97
Chandelier Exit (Long, 3 ATRs) 1.67
Chandelier Exit (Short, 3 ATRs) 2.22
Upper Bollinger Bands 2.11
Lower Bollinger Band 1.69
Percent B (%b) 0.18
BandWidth 21.66
MACD Line 0.02
MACD Signal Line 0.08
MACD Histogram -0.0531
Fundamentals Value
Market Cap 178.82 Million
Num Shares 101 Million
EPS -1.26
Price-to-Earnings (P/E) Ratio -1.40
Price-to-Sales 62.39
Price-to-Book 1.70
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.97
Resistance 3 (R3) 1.96 1.87 1.94
Resistance 2 (R2) 1.87 1.82 1.88 1.93
Resistance 1 (R1) 1.82 1.79 1.85 1.84 1.92
Pivot Point 1.74 1.74 1.75 1.75 1.74
Support 1 (S1) 1.69 1.69 1.71 1.70 1.62
Support 2 (S2) 1.60 1.65 1.61 1.61
Support 3 (S3) 1.55 1.60 1.60
Support 4 (S4) 1.57